Table 2.
COVID-19 vaccines.
| Manufacturer/WHO EUL Holder | Name of Vaccine | Platform | NRA of Record | Recommendation Issued |
|---|---|---|---|---|
| Pfizer Biontech | BNT162b2/COMIRNATY® Tozinameran (INN) | Nucleoside modified mRNA | EMA FDA |
31 December 20 16 July 21 |
| Astra Zeneca | AZD1222 VAXZEVRIA |
Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2 | EMA MFDS KOREA Japan MHLW PMDA Australian TGA |
15 April 21 15 February 21 9 July 21 |
| Serum Institute of India | CovishieldTM (ChAdOx1_nCoV-19) | Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2 | DCGI | 15 February 21 |
| Janssen | Ad26.COV2.S | Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the SARS-CoV-2 Spike (S) protein | EMA | 12 March 21 |
| Moderna | mRNA-1273 SPIKEVAX |
mRNA-based vaccine encapsulated in lipid nanoparticle (LNP) | EMA MFDS FDA |
30 April 21 23 December 21 6 August 21 |
| Sinopharm (Beijing, Wuhan)/BIBP | SARS-CoV-2 Vaccine (Vero Cell), Inactivated (lnCoV) | Inactivated, produced in Vero cells | NMPA | 7 May 21 |
| Sinovac | SARS-CoV-2 Vaccine (Vero Cell), Inactivated (lnCoV) CoronaVac |
Inactivated, produced in Vero cells | NMPA | 1 June 21 |
| The Gamaleya National Center of Epidemiology and Microbiology | Sputnik V | Human adenovirus vector-based COVID-19 vaccine | Russian NRA | 11 August 20 |
| CanSinoBIO- Beijing Institute of Biotechnology | Ad5-nCoV | Inactivated, produced in Vero cells | NMPA | – |
| Bharat Biotech, India | SARS-CoV-2 Vaccine, Inactivated (Vero Cell)/COVAXIN® | Whole-virion inactivated Vero cell | DCGI/CDSCO | 3 November 21 |
| Novavax | NVX-CoV2373/Covovax NUVAXOVID™ |
Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant | EMA | 21 December 21 |
| CureVac | Zorecimeran (INN) concentrate and solvent for dispersion for injection; Company code: CVnCoV/CV07050101 | mRNA-based vaccine encapsulated in lipid nanoparticle (LNP) | EMA | – |
| Sanofi Pasteur | CoV2 preS dTM-AS03 vaccine | Recombinant, adjuvanted | EMA | – |
Adapted from refs. [75,76] Abbreviations: NRA, National Regulatory Agency; EMA, European Medicines Agency; FDA, Food and Drug Administration; MFDS, Ministry of Food and Drug Safety; MHLW, Ministry of Health, Labour, and Welfare; PMDA, Pharmaceuticals and Medical Devices Agency; TGA, Therapeutic Goods Administration; DCGI, Drugs Controller General of India; NMPA, National Medical Products Administration; CDSCO, Central Drugs Standard Control Organization.